Imnovid

Pomalidomide, the active ingredient in Imnovid, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of relapsed or refractory multiple myeloma in adult patients who have received prior therapies.

GNH USA supplies Imnovid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality and regulatory compliance across markets.

Imnovid is an immunomodulatory agent used in the management of multiple myeloma, particularly in patients whose disease has progressed after prior therapies.

- Relapsed multiple myeloma: provides disease control after previous treatment failure. - Refractory multiple myeloma: offers a therapeutic option when disease does not respond to earlier regimens. - Patients previously treated with lenalidomide and bortezomib: extends progression‑free survival in this heavily pre‑treated population.

Adverse reactions to Imnovid may vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell levels causing weakness. - Constipation: decreased bowel movements. - Diarrhea: loose stools. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts requiring medical intervention. - Stevens‑Johnson syndrome: severe skin reaction. - Tumor lysis syndrome: rapid tumor cell breakdown. - Second primary malignancies: emergence of new cancers.

Before initiating Imnovid, several safety considerations should be observed.

- Pregnancy avoidance: contraindicated in pregnancy (Category X). - Teratogenic risk: ensure effective contraception for both patient and partner. - Blood monitoring: perform regular complete blood counts to detect cytopenias. - Infection risk: monitor for signs of infection and manage promptly. - Thromboembolism prophylaxis: assess risk factors and consider anticoagulation when appropriate. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Imnovid may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase pomalidomide exposure. - Strong CYP3A4 inducers: may reduce pomalidomide exposure. - Anticoagulants: increased risk of bleeding. - Live vaccines: contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance sedation. - NSAIDs: may increase risk of thrombocytopenia. - CYP3A4 substrates: may require dose adjustment. - Hormonal contraceptives: efficacy may be reduced, consider alternative methods.